Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Soluble CD163, a marker of adipose tissue macrophage activation, in the etiology of type 2 diabetes
EF 2015-16
Résumé
Obesity is the most well-established and impactful risk factor for the development of type 2 diabetes mellitus (T2DM). Although a number of potential mechanisms have been suggested to explain the obesity-diabetes link, a great deal of research over the past 2 decades has focused on the role of persistent sub-clinical inflammation. Recently, the presence of macrophages in fat tissue was documented, demonstrating the potential importance of fat tissue as a key site of inflammation and source of inflammatory cell signaling proteins. Since direct assessment of fat tissue macrophages is not feasible in large population studies, research points to serum soluble CD163 (sCD163) -a marker of macrophage activation. To date, limited data are available regarding the association of sCD163 with the progression of insulin resistance and pancreatic beta -cell dysfunction - key characteristics underlying T2DM. My master's research will address the current limitations through a long-term population study. I will use the PROspective Metabolism and Islet cell Evaluation (PROMISE) database that includes 712 non-diabetic individuals at high risk for developing T2DM. PROMISE includes demographic data, as well asglucose andinsulin measures throughOral Glucose Tolerance Test atfrom baseline, 3- and 6-year follow ups. Collected data will allow assessment of insulin sensitivity and beta cell function over time. The database will be used to understand how well sCD163 can predict T2DM development and its related pathology. This will help us better grasp the obesity-diabetes relationship, as well as improve risk classification and potentially lead to new therapies in prevention or treatment of T2DM.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
350090
Name
Semnani-Azad Zhila
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Soluble CD163, a marker of adipose tissue macrophage activation, in the etiology of type 2 diabetes
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adipose Tissue; Beta-Cell Function; Biomarkers; Cd163; Epidemiology; Insulin Resistance; Longitudinal; Macrophage; Obesity; Type 2 Diabetes
Abstract
Obesity is the most well-established and impactful risk factor for the development of type 2 diabetes mellitus (T2DM). Although a number of potential mechanisms have been suggested to explain the obesity-diabetes link, a great deal of research over the past 2 decades has focused on the role of persistent sub-clinical inflammation. Recently, the presence of macrophages in fat tissue was documented, demonstrating the potential importance of fat tissue as a key site of inflammation and source of inflammatory cell signaling proteins. Since direct assessment of fat tissue macrophages is not feasible in large population studies, research points to serum soluble CD163 (sCD163) -a marker of macrophage activation. To date, limited data are available regarding the association of sCD163 with the progression of insulin resistance and pancreatic beta -cell dysfunction - key characteristics underlying T2DM. My master's research will address the current limitations through a long-term population study. I will use the PROspective Metabolism and Islet cell Evaluation (PROMISE) database that includes 712 non-diabetic individuals at high risk for developing T2DM. PROMISE includes demographic data, as well asglucose andinsulin measures throughOral Glucose Tolerance Test atfrom baseline, 3- and 6-year follow ups. Collected data will allow assessment of insulin sensitivity and beta cell function over time. The database will be used to understand how well sCD163 can predict T2DM development and its related pathology. This will help us better grasp the obesity-diabetes relationship, as well as improve risk classification and potentially lead to new therapies in prevention or treatment of T2DM.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Semnani-Azad, Zhila
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~